HIV News and Research

RSS

Engineered E. coli Produces Key Plant Compound at Record Levels

Researchers engineered E. coli to produce orsellinic acid-derived meroterpenoids, offering a sustainable alternative to traditional plant extraction methods.

25 Feb 2026

T Immune Cell Transcriptomic Clock Measures Aging in Specific Immune Cells

A new research paper was published in Volume 18 of Aging-US on February 8, 2026, titled "Single-cell transcriptomics reveal intrinsic and systemic T cell aging in COVID-19 and HIV."

20 Feb 2026

Study Reveals New Structural Role for HIV Integrase

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

19 Feb 2026

New Antibodies Prevent EBV Infection in Humanized Mouse Models

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

18 Feb 2026

Microbial Engineering Breakthrough Improves Supply of Promising Pharmaceuticals

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

18 Feb 2026

Study Reveals Planet-Wide Network of Interconnected Microbiomes

In a new study published in Cell, scientists in the Bork Group at EMBL Heidelberg reveal that microbes living in similar habitats are more alike than those simply inhabiting the same geographical region.

10 Feb 2026

Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares' automation platforms beyond T cell therapies into a new cell modality.

From Cellares 8 Feb 2026

DNA Origami Vaccine Scaffolds Sharpen Immune Targeting Against HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

New Epigenetic Catalog Helps Explain Individual Differences in Immune Responses

The COVID-19 pandemic gave us tremendous perspective on how wildly symptoms and outcomes can vary between patients experiencing the same infection.

28 Jan 2026

A Hidden Nanomachine Behind Constant Cellular Secretion

Scientists uncover the tiny machine that delivers essential molecular packages to the cell surface, a fundamental activity for maintaining healthy cells.

19 Jan 2026

Antibody 04_A06 Neutralizes Nearly All Tested HIV Variants in Laboratory Studies

A Cologne-led research team has discovered the antibody 04_A06, which neutralizes the human immunodeficiency virus (HIV) in almost all tested variants in vitro and even overcomes typical resistance mechanisms.

7 Oct 2025

Study Reveals Tissue-Specific DNA Patterns Used by HIV to Evade Detection

Researchers at Western University and the University of Calgary have discovered how HIV hides in different parts of the body by embedding itself into the DNA of cells in a tissue-specific manner, offering new insights into why the virus is so difficult to eliminate and cure – even decades after infection and treatment.

7 Oct 2025